ReviewVascular health and risk management2006
Insulin glargine in the treatment of type 1 and type 2 diabetes.
Review in Vascular health and risk management, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 43 citations in OpenAlex.
- Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.Diabetes & metabolism journal · 2019Trial
- Economic evaluation of insulin glargine compared with human insulin for youth with type 1 diabetes in Tanzania and Bangladesh.PloS one · 2026Article
- Impact of switching from neutral protamine hagedorn insulin (NPH) to glargine insulin on glycemic control and clinical outcomes in pediatric patients with type 1 diabetes.Exploratory research in clinical and social pharmacy · 2025Article
- A Century of Progress in Diabetes Care with Insulin: A History of Innovations and Foundation for the Future.Diabetes & metabolism journal · 2021Review
- Improved Methods for Mid-Term Blood Glucose Level Prediction Using Dietary and Insulin Logs.Medicina (Kaunas, Lithuania) · 2021Article
- Hypoglycemic episodes in hospitalized people with diabetes in Portugal: the HIPOS-WARD study.Clinical diabetes and endocrinology · 2021Article
- Article
- Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2017Review
- The Affordable Care Act and Diabetes Diagnosis and Care: Exploring the Potential Impacts.Current diabetes reports · 2016Review
- Effects of exercise training combined with insulin treatment on cardiac NOS1 signaling pathways in type 1 diabetic rats.Molecular and cellular biochemistry · 2011Article
- Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.Vascular health and risk management · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin glargine is an analogue of human insulin that is modified to provide a consistent level of plasma insulin over a long duration. Pharmacokinetic and pharmacodynamic studies show that a single injection of insulin glargine leads to a smooth 24-hour time-action profile with no undesirable pronounced peaks of activity. In clinical trials, this profile has been associated with at least equivalent, if not better, glycemic control than other traditional basal insulins and a significantly lower rate of overall and nocturnal hypoglycemia. The convenience of a once-daily injection, a lack of need for resuspension (insulin glargine is a clear solution when injected), and lower rates of hypoglycemia should translate into improvements in patient treatment satisfaction. This review appraises the evidence for the view that insulin glargine represents an advance in basal insulin therapy for both type 1 and type 2 diabetes patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.